Solubilization of rapamycin

International Journal of Pharmaceutics

Volumn 213, Issue 1-2, 2001, Pages 25-29

  Simamora, Pahala ^a   Alvarez, Joan M ^b   Yalkowsky, Samuel H ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cosolvent; Hydrotrope; Hydrotropy; Rapamycin; Solubility; Solubilization

Indexed keywords

ALCOHOL; BENZOIC ACID; BENZYL ALCOHOL; IMMUNOSUPPRESSIVE AGENT; PROPYLENE GLYCOL; RAPAMYCIN;

ARTICLE; DRUG EFFECT; DRUG SOLUBILITY; MISCIBILITY; PRIORITY JOURNAL; SOLUBILIZATION;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; SIROLIMUS; SOLUBILITY; SOLVENTS;

EID: 0035253757     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00617-7     Document Type: Article

References (19)

1. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
2. Rapamycin prolongs survival of murine recipients of fully allogenic donor grafts when administered during the graft-versus-host disease process
3. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogenic T-cell-depleted donor marrow
4. Distinct mechanisms of suppression of murine T-cells activation by the related macrolides FK 506 and rapamycin
5. Solubility of anthracene in complex solvent systems
6. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro
7. Inhibition of the immune response by rapamycin, a new antifungal antibiotic
8. Rapamycin (RAPA, rapamycin, sirolimus): Mechanism of action of immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression
9. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, characterization
10. Rapamycin (AY-22,989), a new antifungal antibiotic: IV. Mechanism of action
11. Synergistic effect of cyclosporine and rapamycin on heart and kidney allograft survival in rats
12. Prolongation by rapamycin of heart, kidney, pancreas and small bowel allograft survival in rat
13. Parenteral formulations of small molecules therapeutics marketed in the United States (1999) - Part I. PDA
14. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle
15. Review of excipients and pH's for parenteral products used in the United States